VERASTEM, INC. (VSTM)
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
📈 **POSITIVE** • High confidence analysis (93%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business